Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds

A compound selected from those of Formula (I) and pharmaceutically accepted salts thereof:

• wherein
• Cy1 is cycloalkylidene or heterocycloalkylidene;
• R1 and R2 are independently selected from the group consisting of:
• (a) H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, and arylalkyl;
• and
• (b) R8—C(O)—X1—, R8—O—C(O)—X1— and R8—S(O)a—X1—,
• wherein X1 is selected from the group consisting of a bond, —NH—C1-6 alkylene, —O—C1-6 alkylene, C1-6 alkylene, C2-6 akenylene, C2-6 alkynylene, C3-6 cycloalkylene, arylene, and heterocyclylene;
• R8 is selected from the group consisting of H, hydroxy, amino, alkyl, alkoxy, N-alkylamino, N,N-dialkylamino, cycloalkyl, and heterocyclyl;
• and
• a is 0, 1 or 2;
• wherein each R1 and R2 is optionally substituted with one or more A where such an optional substitution is chemically feasible;
• R3 is independently selected from the group consisting of:
• (a) cyano, oxo, halo, nitro, hydroxy, amino, mercapto, alkyl, aryl, cycloalkyl, heterocyclyl, and heterocyclylalkyl;
• (b) R9—C(O)—X2—, R9—O—C(O)—X2— and R9—S(O)a—X2—,
• wherein X2 is selected from the group consisting of a bond, —NH—C1-6 alkylene, —O—C1-6 alkylene, C1-6 alkylene, C2-6 akenylene, C2-6 alkynylene, C3-6 cycloalkylene, arylene, and heterocyclylene;
• and
• a is 0, 1 or 2,
• wherein R1 is optionally substituted with one or more B where such an optional substitution is chemically feasible;
• or
• when m is 2, the two R1 groups can be substituted on the same carbon ring atom of Cy and together with the carbon ring atom of Cy for in a ring situated on Cy in a spiro configuration, wherein the spiro ring is cycloalkyl or heterocycloalkyl;
• two groups R3 are substituted on the same carbon ring atom of Cy1 and together with the carbon ring atom of Cy1 form a ring situated on Cy1 in a spiro configuration, wherein the spiro ring is cycloalkyl or heterocycloalkyl;
• m is an integer from 0 to the maximum number of substitutable positions on Cy1;
• R4 is selected from the group consisting of —H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, aralkyl, heteroaralkyl, alkylamino, alkylaminoalkyl, cycloalkylamino, heterocycloalkylamino, and arylamino, wherein R4 is optionally substituted with one or more selected from halo, oxo, hydroxyl, amino, alkylamino, carbamoyloxy, carbamoyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl where such an optional substitution is chemically feasible;
• R5 is independently selected from the group consisting of halo, hydroxy, nitro, cyano, haloalkyl, haloalkoxy, amino, carboxy, carbamoyl, sulphamoyl, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C1-10 alkoxy, C1-10 alkanoyl, N—(C1-10 alkyl)amino, N,N—(C1-10 alkyl)2 amino, C1-10 alkanoylamino, N—(C1-10 alkyl)carbamoyl, N,N—(C1-10 alkyl)2 carbamoyl, C1-10 alkyl-S(O)a wherein a is 0, 1 or 2, NH2—S(O)2NH—, N—(C1-10 alkyl)sulphamoyl, N,N—(C1-10 alkyl)2sulphamoyl, cycloalkyl, heterocyclyl and aryl;
• n is 0, 1, 2, 3 or 4;
• R6 is independently selected from the group consisting of —H, halo, haloalkyl, aryl and heteroaryl wherein the aryl or heteroaryl is optionally substituted with one or more substituents selected from the group consisting of amino, halo, alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl;
• o is 0, 1, 2, 3 or 4;
• R7 is NH2— or OH—;
• A is independently selected from the group consisting of oxo, halo, amino, hydroxyl, cyano, carbamoyl, C1-10 alkyl, C1-10 alkoxy, C1-10 haloalkyl, C1-10 alkanoylamino, N—(C1-10 alkyl)amino, N,N—(C1-10 dialkyl)amino, C1-10 alkanoyl, N—(C1-10 alkyl)carbamoyl, N,N—(C1-10 dialkyl)carbamoyl, C3-10 cycloalkyl, (C3-10 cycloalkyl)C1-10 alkyl, C3-10 cycloalkoxy, C1-10 haloalkoxy, heterocycloalkyl, (heterocycloalkyl)C1-10 alkyl, aryl, (aryl)C1-10 alkyl, heteroaryl, (heteroaryl)C1-10 alkyl and R(R′)(R″)silyl wherein R, R′ and R″ are independently alkyl or aryl, or
• when R1 or R2 is a saturated or unsaturated cyclic group, two A groups can be substituted at adjacent positions of R1 or R2 and form a 5- or 6-membered, saturated or unsaturated cyclic moiety to make a fused ring with R1 or R2, wherein the cyclic moiety can contain one or more heteroatoms selected from N, O and S;
• and
• B is independently selected from the group consisting of halo, amino, carboxy, carbamoyl, C1-10 alkyl, C1-10 alkoxy, N—(C1-10 alkyl)amino, N,N—(C1-10 dialkyl)amino, N—(C1-10 alkyl)carbamoyl, N,N—(C1-10 dialkyl)carbamoyl, C1-10 haloalkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 aryl, heteroaryl, (C1-10 alkyl)C3-10 cycloalkyl and R(R′)(R″)silyl wherein R, R′ and R″ are independently alkyl or aryl.